End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.61 CNY | -2.76% | -5.51% | -19.98% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.98% | 870M | - | ||
-39.26% | 13.9B | B- | ||
-32.35% | 10.68B | B | ||
-16.27% | 7.12B | B | ||
+10.79% | 6.24B | C | ||
-11.61% | 5.96B | C+ | ||
+73.30% | 4.72B | C | ||
-3.50% | 4.56B | D- | ||
-6.67% | 3.87B | B | ||
-19.80% | 3.17B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 605266 Stock
- Ratings Jianzhijia Pharmaceutical Chain Group Co., Ltd.